AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6779371
Drug: Phenoxymethyl penicillin
RxNorm normalized name: Phenoxymethyl Penicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenoxymethyl penicillin (1.6 g daily)
Trial: 30378087
Drug: Glycopyrronium tosylate
RxNorm normalized name: glycopyrronium tosylate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium tosylate (GT) 3.75% applied once daily for 4 weeks
Trial: 25881461
Drug: Xingnaojing Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xingnaojing Injection (20 mL per day for 14 days), followed by Chinese medical granules for 21 days, and Naoxueshu Oral Liquid (10 mL, 3 times per day till 3 months)
Trial: 25881461
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment of Western internal medicine
Trial: 19729890
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus oral cholecalciferol (150,000 IU once a month for the first 2 months, followed by 90,000 IU once a month for the last 4 months)
Trial: 19729890
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus monthly placebo
Trial: 11718495
Drug: Cycloserine 500
RxNorm normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycloserine 500 mg after a 12-hour fast (reference)
Trial: 11718495
Drug: Cycloserine 500
RxNorm normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycloserine 500 mg with a high-fat meal
Trial: 11718495
Drug: Cycloserine 500
RxNorm normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycloserine 500 mg with orange juice
Trial: 11718495
Drug: Cycloserine 500
RxNorm normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycloserine 500 mg with antacids
Trial: 8239101
Drug: Flumazenil (1
RxNorm normalized name: Flumazenil (18-F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (1 mg/10 mL) administered at 10 mL/min for ten minutes, with up to 3 mg of open-label flumazenil if no response.
Trial: 8239101
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 mL/min) administered for ten minutes.
Trial: 23661528
Drug: Food supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food supplement containing forskolin, rutin, and vitamins B1 and B2 for 30 days
Trial: 18579283
Drug: Conventional conservative
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional conservative preparation (G1)
Trial: 18579283
Drug: Modified preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified preparation with cavosurface bevel (G2)
Trial: 16636486
Drug: Tirofiban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban (10 mg/kg bolus followed by infusion of 0.15 mg . kg(‐1) . min (‐1) until total dose reached 12.5 mg)
Trial: 12006956
Drug: L-arginine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine supplementation (1.5 mmol/kg per day)
Trial: 7473451
Drug: 0.6 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/d of conjugated equine estrogen (CEE) cyclically (n = 15)
Trial: 7473451
Drug: 50 micrograms/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms/d of transdermal estradiol (E2) cyclically (n = 17)
Trial: 7473451
Drug: 0.6 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/d of CEE continuously (n = 17)
Trial: 7473451
Drug: 0.625 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/d of CEE and 2.5 mg/d of MPA continuously (n = 19)
Trial: 7473451
Drug: Treatment-free control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-free control group (n = 22)
Trial: 6315329
Drug: Cimetidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1 g daily for two weeks)
Trial: 6315329
Drug: Nifedipine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (4 X 10 mg daily for four weeks)
Trial: 6315329
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg daily for two weeks)
Trial: 6315329
Drug: Nifedipine alone
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine alone (4 X 10 mg daily)
Trial: 31626571
Drug: Stage-adapted first-line
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stage-adapted first-line treatment (radiotherapy alone, chemotherapy alone, or combined-modality approaches)
Trial: 30275228
Drug: Intraperitoneal paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intraperitoneal paclitaxel followed by paclitaxel, cisplatin, and S‐1 (PCS) chemotherapy
Trial: 25549086
Drug: Artemisinin-naphthoquine (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin-naphthoquine (three daily doses)
Trial: 25549086
Drug: Artemether-lumefantrine (six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (six doses over 3 days)
Trial: 22332205
Drug: High ω‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High ω‐3 intake (≥0.20 g/d)
Trial: 22332205
Drug: Low ω‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low ω‐3 intake (<0.20 g/d)
Trial: 19996989
Drug: Exercise program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise program (Sex Hormones and Physical Exercise study)
Trial: 15972582
Drug: Once-monthly oral
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-monthly oral ibandronate 150 mg
Trial: 15972582
Drug: Once-monthly oral
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-monthly oral ibandronate 100 mg
Trial: 10720074
Drug: Low-insulin-hypoglycemic condition
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-insulin-hypoglycemic condition (insulin infusion at 1.5 mU/min x kg)
Trial: 10720074
Drug: High-insulin-hypoglycemic condition
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-insulin-hypoglycemic condition (insulin infusion at 15.0 mU/min x kg)
Trial: 10720074
Drug: Low-insulin-euglycemic condition
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-insulin-euglycemic condition (insulin infusion at 1.5 mU/min x kg)
Trial: 10720074
Drug: High-insulin-euglycemic condition
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-insulin-euglycemic condition (insulin infusion at 15.0 mU/min x kg)
Trial: 1611649
Drug: Lovastatin 20
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20 mg QD
Trial: 1611649
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg QD
Trial: 1611649
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg QD
Trial: 6140343
Drug: Oestradiol and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestradiol and testosterone implants
Trial: 30561059
Drug: Telmisartan 2
RxNorm normalized name: telmisartan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 2 mg/kg q24 PO
Trial: 18191732
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (200 mg weekly until ferritin >500 ng/ml, 200 mg monthly thereafter)
Trial: 16393724
Drug: Nebulized beta2-agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized beta2-agonist
Trial: 9869598
Drug: Infliximab (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5-20 mg/kg)
Trial: 8703705
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium loading test
Trial: 26856618
Drug: Oral dydrogesterone
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dydrogesterone (20mg daily)
Trial: 20298820
Drug: Partial body
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial body weight-supported treadmill training (PBWSTT) for 9 weeks, twice weekly.
Trial: 20298820
Drug: Overground walking
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Overground walking practice for 9 weeks, twice weekly.
Trial: 17381930
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of price discounts and nutrition education
Trial: 11731813
Drug: 17D yellow
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen Injection [Stamaril]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17D yellow fever vaccine administered at 6 months
Trial: 11731813
Drug: 17D yellow
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen Injection [Stamaril]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17D yellow fever vaccine administered at 9 months
Trial: 28185672
Drug: Cariprazine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine (mean daily dose 4.2 mg)
Trial: 28185672
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean daily dose 3.8 mg)
Trial: 17928726
Drug: IgY‐GP gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgY‐GP gel subgingivally applied with subgingival scaling and root planing
Trial: 17928726
Drug: IgY‐GP gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgY‐GP gel
Trial: 15764039
Drug: UVA/UVB +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVA/UVB + topical corticosteroids (Group II)
Trial: 7805972
Drug: Ritodrine tablets
DrugBank: Ritodrine (DB00867)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ritodrine tablets
Trial: 7805972
Drug: Sustained-release capsules
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release capsules
Trial: 25380107
Drug: 3% or
RxNorm normalized name: Esopho-Cat, 3% oral cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% or 23.4% hypertonic saline (HTS) as bolus therapy
Trial: 21618480
Drug: Avotermin 500
RxNorm normalized name: avotermin
DrugBank: Avotermin (DB11955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avotermin 500 ng per 100 µl per linear cm of wound margin, administered by intradermal injection to the groin and distal wound margins of one leg.
Trial: 21618480
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered to the other leg.
Trial: 15865549
Drug: Piperacillin/tazobactam (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (4 g/0.5 g q8h)
Trial: 15865549
Drug: Ampicillin/sulbactam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin/sulbactam (2 g/1 g q6h)
Trial: 11206417
Drug: Insulin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (1 mU/kg/min)
Trial: 11206417
Drug: Insulin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (2 mU/kg/min)
Trial: 11206417
Drug: Hyperglycaemia (5.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemia (5.6 mmol/l, 11.1 mmol/l, 16.7 mmol/l)
Trial: 11206417
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + Hyperglycaemia with somatostatin
Trial: 9205656
Drug: Saliva Orthana
RxNorm normalized name: AS Saliva Orthana
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saliva Orthana (mucin-containing oral spray)
Trial: 9205656
Drug: Placebo (mucin-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (mucin-free spray)
Trial: 8440931
Drug: D protein
RxNorm normalized name: Bird protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D protein vaccine (500 micrograms)
Trial: 8440931
Drug: D protein
RxNorm normalized name: Bird protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D protein vaccine
Trial: 28350401
Drug: Lipopolysaccharide (LPS)
RxNorm normalized name: sulfated mucopolysaccharides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipopolysaccharide (LPS) pre-treatment
Trial: 28350401
Drug: Placebo (PBO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PBO) pre-treatment
Trial: 26143536
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin treatment
Trial: 22767151
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of TER
Trial: 21148518
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP)
Trial: 15344541
Drug: Lansoprazole (LPZ)
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole (LPZ) 30 mg/day
Trial: 15344541
Drug: Lansoprazole (LPZ)
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole (LPZ) 15 mg/day
Trial: 15344541
Drug: Famotidine (FAM)
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Famotidine (FAM) 40 mg/day
Trial: 11002217
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion (HAI) with 5‐FU at 600 mg/m(2)/day for 2 consecutive days per week and oral UFT at 400 mg/day for 5‐7 days per week, repeated 10 times (Group A)
Trial: 11002217
Drug: Oral UFT
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral UFT at 400 mg/day for 6 months (Group B)
Trial: 9021437
Drug: Oral fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fenoterol 2.5 mg 3 times daily
Trial: 7940144
Drug: Timolol 0.25%
RxNorm normalized name: Timolol 0.25% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.25% eyedrops (during treatment)
Trial: 7940144
Drug: Timolol withdrawn
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol withdrawn (off treatment)
Trial: 3064818
Drug: Fresh human
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh human milk or fortified human milk with protein intake of 2.1 to 3.3 g/kg/day
Trial: 18318773
Drug: Udenafil 25
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil 25 mg
Trial: 18318773
Drug: Udenafil 300
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil 300 mg
Trial: 18318773
Drug: Udenafil 100
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil 100 mg (multiple dose)
Trial: 18318773
Drug: Udenafil 200
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil 200 mg (multiple dose)
Trial: 12830439
Drug: Short daily
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short daily hemodialysis (HD)
Trial: 12830439
Drug: Conventional thrice-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional thrice-weekly hemodialysis (HD)
Trial: 8887197
Drug: Growth hormone-releasing
RxNorm normalized name: Growth hormone-releasing peptide 2
DrugBank: Pralmorelin (DB18252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Growth hormone-releasing factor (GRF), 1,000 mg/day, given in addition to follicle-stimulating hormone (FSH)
Trial: 8887197
Drug: Follicle-stimulating hormone
RxNorm normalized name: Follicle-stimulating hormone receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follicle-stimulating hormone (FSH) alone (control group)
Trial: 8887197
Drug: Growth hormone-releasing
RxNorm normalized name: Growth hormone-releasing peptide 2
DrugBank: Pralmorelin (DB18252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Growth hormone-releasing factor (GRF) with FSH
Trial: 1355943
Drug: Standard nonspecific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nonspecific treatment
Trial: 6148163
Drug: Thyroid stimulating
RxNorm normalized name: Thyroid stimulating hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid stimulating antibody (TSAb) determinations before and at the end of treatment
Trial: 6148163
Drug: End-treatment TSAb
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End-treatment TSAb levels greater than 350%
Trial: 6148163
Drug: End-treatment TSAb
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End-treatment TSAb levels less than 350% or negative
Trial: 3789694
Drug: Interferon (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (3 X 10(6) IU of alpha 2b interferon, administered by subcutaneous injection, three times weekly for 12 weeks)
Trial: 3789694
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered by subcutaneous injection, three times weekly for 12 weeks)
Trial: 28177728
Drug: Daily light
RxNorm normalized name: TITANIUM DIOXIDE 63 mg in 1 mL / ZINC OXIDE 41 mg in 1 mL TOPICAL LOTION [DAILY LIGHT GUARD DEFENSE FLUID BROAD SPECTRUM SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily light physical activity for a minimum of 30 minutes starting a maximum of 30 minutes after a meal for 12 weeks
Trial: 16563900
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose infusion (1 L) prior to catheterization
Trial: 16563900
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no dextrose infusion)
Trial: 11746615
Drug: tolcapone 100
RxNorm normalized name: tolcapone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolcapone 100 mg t.i.d. (possible increase to 200 mg t.i.d.)
Trial: 11746615
Drug: pergolide titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pergolide titrated to a maximum dose of 5 mg/day (mean final dose 2.2 mg/day)
Trial: 2442506
Drug: Nisoldipine (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (10-40 mg daily)
Trial: 2442506
Drug: Verapamil (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (40-80 mg three times daily)
Trial: 2442506
Drug: Nifedipine (long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (long-acting form, 20-80 mg daily)
Trial: 31618099
Drug: PES-G (grandiose-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PES-G (grandiose-based entitlement)
Trial: 28315068
Drug: nab-paclitaxel 150
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 150 mg/m2 (nP150)
Trial: 28315068
Drug: nab-paclitaxel 125
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 125 mg/m2 (nP125)
Trial: 28315068
Drug: paclitaxel 80
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel 80 mg/m2 (P80)
Trial: 18089850
Drug: Arm A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: 6 weeks of daily prednisone and weekly vinblastine followed by 18 weeks of daily 6‐mercaptopurine with vinblastine/prednisone pulses
Trial: 18089850
Drug: Arm B
RxNorm normalized name: arm brace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B (intensified treatment)
Trial: 16514225
Drug: 1 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml/kg of 25 microg/kg butorphanol in combination with 0.25% bupivacaine
Trial: 16514225
Drug: 1 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml/kg of 0.25% bupivacaine
Trial: 16514225
Drug: 1 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml/kg of 25 microg/kg butorphanol diluted in normal saline
Trial: 10790348
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 20 ppm nitric oxide (NO)
Trial: 12580112
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug treatment
Trial: 3510014
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics (2 g for eight doses)
Trial: 3510014
Drug: Irrigation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigation of uterus and peritoneum with 2 g of antibiotic
Trial: 3510014
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intravenous and irrigation
Trial: 28703859
Drug: 19 or
RxNorm normalized name: pediatric multivitamin no.119 ORAL TABLET,CHEWABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19 or 38 mg iron for 60 days